First-Line Vasoactive Drugs for Pediatric Septic Shock

2016 ◽  
Vol 44 (4) ◽  
pp. e232-e233 ◽  
Author(s):  
José Colleti ◽  
Werther Brunow de Carvalho
2015 ◽  
Vol 43 (11) ◽  
pp. 2292-2302 ◽  
Author(s):  
Andréa M. C. Ventura ◽  
Huei Hsin Shieh ◽  
Albert Bousso ◽  
Patrícia F. Góes ◽  
Iracema de Cássia F. O. Fernandes ◽  
...  

2016 ◽  
Vol 60 (5) ◽  
pp. 205-206
Author(s):  
Andréa M. C. Ventura ◽  
Huei Hsin Shieh ◽  
Albert Bousso ◽  
Patrícia F. Góes ◽  
Iracema de Cássia F. O. Fernandes ◽  
...  

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Tim G. Kampmeier ◽  
Philip H. Arnemann ◽  
Michael Hessler ◽  
Laura M. Seidel ◽  
Karsten Becker ◽  
...  
Keyword(s):  

Author(s):  
Fiona Roberts ◽  
Alan Gaffney

This chapter discusses vasodilatory shock. The hallmark of vasodilatory shock is hypotension with normal or increased cardiac output. The hyperdynamic circulatory state of vasodilatory shock results in a tachycardia and an increased pulse pressure. Radiological and biochemical investigations can assist with determining the diagnosis of shock. The causes of vasodilatory shock are diverse; they include sepsis, surgical insult, anaphylaxis, and others such as trauma, burns, and pancreatitis. However, sepsis is by far the most common cause of vasodilatory shock. The pathophysiology of vasodilatory shock is also complex and multifactorial. Although still not fully understood, it is widely accepted that it includes activation of several intrinsic vasodilatory pathways and a vascular hyporesponsiveness to vasopressors. Early fluid resuscitation and appropriate antimicrobial therapy are the most crucial treatment interventions in septic shock. Meanwhile, noradrenaline is the first-line vasopressor of choice in septic shock.


1998 ◽  
Vol 26 (8) ◽  
pp. 1459-1460
Author(s):  
Andreas Meier-Hellmann ◽  
Konrad Reinhart ◽  
Donald L. Bredle ◽  
Martin Specht

2016 ◽  
Vol 51 (3) ◽  
pp. 194-202 ◽  
Author(s):  
Nina Vadiei ◽  
Mitchell J. Daley ◽  
Manasa S. Murthy ◽  
Carrie S. Shuman

Background: Currently, a lack of standardization exists in norepinephrine dosing units, the first-line vasopressor for septic shock. Timely achievement of goal mean arterial pressure (MAP) is dependent on optimal vasopressor dosing. Objective: To determine if weight-based dosing (WBD) of norepinephrine leads to earlier time to goal MAP compared with non-WBD in obese patients with septic shock. Methods: This was a retrospective, multicenter cohort study. Patients had a body mass index (BMI) ≥30 kg/m2 and received norepinephrine for septic shock with either a non-WBD strategy (between December 2009 and January 2013) or WBD strategy (between January 2013 and December 2015). The primary outcome was time to goal MAP. Secondary outcomes were norepinephrine duration, dose requirements, and development of treatment-related complications. Results: A total of 287 patients were included (WBD 144; non-WBD 143). There was no difference in median time to goal MAP (WBD 58 minutes, interquartile range [IQR] = 16.8-118.5, vs non-WBD 60 minutes, IQR = 17.5-193.5; P = 0.28). However, there was a difference in median cumulative norepinephrine dose (WBD 12.6 mg, IQR = 4.9-45.9, vs non-WBD 10.5 mg, IQR = 3.9-25.6; P = 0.04) and time to norepinephrine discontinuation (WBD 33 hours, IQR = 15-69, vs non-WBD 27 hours, IQR = 12-51; P = 0.03). There was no difference in rates of atrial fibrillation (WBD 15.3% vs non-WBD 23.7%; P = 0.07) or mortality (WBD 23.6% vs non-WBD 23.1%; P = 0.92). Conclusion: WBD of norepinephrine does not achieve time to goal MAP earlier in obese patients with septic shock. However, WBD may lead to higher norepinephrine cumulative dose requirements and prolonged time until norepinephrine discontinuation.


1980 ◽  
Vol 8 (3) ◽  
pp. 289-309 ◽  
Author(s):  
W. B. Runciman

The autonomic nervous system may play an important role in tissue autoregulation as the neurohumoral transmission process has been shown to constitute the final common pathway by which the effects of many physiological and pharmacological substances are mediated. The effects of the administration of a sympathomimetic amine cannot be accurately predicted in a subject. Choice of which sympathomimetic amine to use should be determined on the basis of data obtained in relevant clinical circumstances, but the dose should always be titrated against the effect in each individual. It is interesting that adrenaline, “the original autonomic drug” with its “venerable history”,56 is still a first line drug in many of the situations for which it was being prescribed in 1907. It is the drug of first choice in anaphylactic reactions and for severe allergic bronchospasm, and is widely used as a vasoconstrictor in surgery and with local anaesthetic agents. Adrenaline in “physiological” doses is a satisfactory and cheap alternative to other available drugs for use in septic shock and in emergence from cardiopulmonary bypass.


2009 ◽  
Vol 35 (7) ◽  
pp. 1286-1296 ◽  
Author(s):  
Sebastian Rehberg ◽  
Christian Ertmer ◽  
Gabriele Köhler ◽  
Hans-Ulrich Spiegel ◽  
Andrea Morelli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document